

Resource Summary Report

Generated by [Kravitz](#) on Sep 19, 2026

NOD.Cg-Prkdc^{scid} Il2rg/SzJ

RRID:IMSR_JAX:005557

Type: Organism

Proper Citation

RRID:IMSR_JAX:005557

Organism Information

URL: <https://www.jax.org/strain/005557>

Proper Citation: RRID:IMSR_JAX:005557

Description: Mus musculus with name NOD.Cg-Prkdc^{scid} Il2rg/SzJ from IMSR.

Species: Mus musculus

Synonyms: NOD-scid IL2Rg. NSG. NOD scid gamma. NOD-scid IL2Rgamma

Notes: gene symbol note: protein kinase; DNA activated; catalytic polypeptide|interleukin 2 receptor; gamma chain; mutant strain|congenic strain: Prkdc|Il2rg

Affected Gene: protein kinase; DNA activated; catalytic polypeptide|interleukin 2 receptor; gamma chain

Genomic Alteration: severe combined immunodeficiency|targeted mutation 1; Warren J Leonard

Catalog Number: JAX:005557

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: live

Organism Name: NOD.Cg-Prkdc^{scid} Il2rg/SzJ

Record Creation Time: 20250513T053650+0000

Record Last Update: 20260919T054840+0000

Ratings and Alerts

- Used for genotyping by the Human Islet Research Network community. Contact(s): Seung Kim, Simona Chera, Pedro Herrera, Charles Chang - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for NOD.Cg-Prkdc^{scid} Il2rg/SzJ.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 1054 mentions in open access literature.

Listed below are recent publications. The full list is available at [Kravitz](#) .

Kishimoto S, et al. (2026) Band-Selective IR PRESS for Brain Tumor Spectroscopy Allows Robust Detection of Lactate. NMR in biomedicine, 39(3), e70220.

Stoiber S, et al. (2026) [18F]FDG PET/CT multiomics identifies Hedgehog-driven HPV-negative head and neck squamous cell carcinoma. Molecular cancer, 25(1).

Peterson NC, et al. (2026) Development of a Plasma Spot Assay for Detection of Fluorophore-labeled Antibodies in Mouse Imaging Studies. In vivo (Athens, Greece), 40(4), 1904.

Çak?lkaya P, et al. (2026) Targeting uPARAP with an Antibody-Drug Conjugate Exhibits Efficacy against Mesothelioma and Synergizes with Cisplatin. Cancer research communications, 6(1), 130.

Chung IC, et al. (2026) Extracellular Enolase-1 Promotes CAF-Associated Stromal Reprogramming via the Plasmin/TGF-? Axis in Multiple Myeloma. Cancers, 18(9).

Mansell RP, et al. (2026) Ether lipids influence cancer cell fate by modulating iron uptake. Nature communications, 17(1), 1835.

Berry BC, et al. (2026) Epigenetic buffering of proteotoxic stress by EHMT2 enables meningioma growth. Neuro-oncology advances, 8(1), vdag037.

Wang JG, et al. (2026) The long noncoding RNA Inc-FAM164A1-ACLY axis promotes pro-inflammatory responses in human primary macrophages: a systems approach. Frontiers in immunology, 17, 1776849.

Wagner KK, et al. (2026) Xenograft tissue slice tandem co-cultures are a highly specific model to selectively analyze drug inhibitory effects on glioblastoma invasion. The Journal of biological chemistry, 302(1), 110986.

Feng Z, et al. (2026) Engineered VPg saRNA achieves cap-independent, low-immunogenic and precise encoding of therapeutic proteins in vivo. *Nature communications*, 17(1), 1666.

Barajas JM, et al. (2026) Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency. *Blood cancer discovery*, 7(1), 51.

Kehm H, et al. (2026) Dissection of the T cell infiltrate in mouse pancreatic tumors reveals an extensive and diverse tumor-reactive T cell repertoire. *Science advances*, 12(15), eadr6132.

Kim M, et al. (2026) Bone Metastatic Progression of Prostate Cancer Is Regulated by TRIM28-LDHA-Mediated Metabolism. *Molecular cancer research : MCR*, 24(2), 93.

García-Vicente R, et al. (2026) The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(2), 375.

Gumpert N, et al. (2026) Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer. *Cancer discovery*, 16(2), 250.

López-Fuentes E, et al. (2026) Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities. *Cancer discovery*, 16(2), 296.

Facchinetti F, et al. (2026) Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(8), 1574.

Liu ACH, et al. (2026) Single-cell proteogenomic analysis of clonal evolution in PDX models of AML treated with IDH inhibitors. *Blood neoplasia*, 3(1), 100182.

Takeda S, et al. (2026) A MERTK-Targeting Antibody-Drug Conjugate Selectively Depletes M2 Tumor-Associated Macrophages and MERTK-Expressing Cancer Cells. *Cancer research*, 86(8), 2024.

Yuan F, et al. (2026) Glioblastoma stem cells resist cuproptosis with circadian variation of copper levels. *The Journal of clinical investigation*, 136(1).